Lineage Cell Therapeutics, Inc. (LCTX)
1.015
-0.02
(-1.46%)
USD |
NYAM |
Oct 09, 10:06
Lineage Cell Therapeutics EPS Diluted (Quarterly) : -0.0304 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0304 |
| March 31, 2026 | -0.0273 |
| December 31, 2025 | 0.0035 |
| September 30, 2025 | -0.1301 |
| June 30, 2025 | -0.1334 |
| March 31, 2025 | -0.0183 |
| December 31, 2024 | -0.0148 |
| September 30, 2024 | -0.0161 |
| June 30, 2024 | -0.0305 |
| March 31, 2024 | -0.0358 |
| December 31, 2023 | -0.0277 |
| September 30, 2023 | -0.0407 |
| June 30, 2023 | -0.0306 |
| March 31, 2023 | -0.0257 |
| December 31, 2022 | -0.0374 |
| September 30, 2022 | -0.0357 |
| June 30, 2022 | -0.0398 |
| March 31, 2022 | -0.0418 |
| December 31, 2021 | -0.1711 |
| September 30, 2021 | -0.0467 |
| June 30, 2021 | -0.0294 |
| March 31, 2021 | -0.0089 |
| December 31, 2020 | 0.0133 |
| September 30, 2020 | -0.0517 |
| June 30, 2020 | -0.0435 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.0561 |
| December 31, 2019 | -0.0299 |
| September 30, 2019 | -0.1103 |
| June 30, 2019 | -0.2008 |
| March 31, 2019 | 0.2959 |
| December 31, 2018 | -0.354 |
| September 30, 2018 | 0.5255 |
| June 30, 2018 | -0.03 |
| March 31, 2018 | -0.5009 |
| December 31, 2017 | -0.58 |
| September 30, 2017 | 0.12 |
| June 30, 2017 | -0.11 |
| March 31, 2017 | 0.46 |
| December 31, 2016 | -0.05 |
| September 30, 2016 | 0.30 |
| June 30, 2016 | 0.26 |
| March 31, 2016 | -0.19 |
| December 31, 2015 | -0.16 |
| September 30, 2015 | -0.18 |
| June 30, 2015 | -0.12 |
| March 31, 2015 | -0.13 |
| December 31, 2014 | -0.14 |
| September 30, 2014 | -0.12 |
| June 30, 2014 | -0.16 |
| March 31, 2014 | -0.14 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 4.366 |
| BioCryst Pharmaceuticals, Inc. | 0.2957 |
| Imunon, Inc. | -0.5412 |
| Curis, Inc. | -4.017 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 1.544M |
| Revenue (Quarterly) | 1.069M |
| Total Expenses (Quarterly) | -0.413M |
| Enterprise Value | 210.85M |
| Gross Profit Margin (Quarterly) | 82.51% |
| Earnings Yield | -18.16% |
| Normalized Earnings Yield | -13.64 |